Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

Until then, my family chooses to remain thankful for the available PF treatments and hopeful about the advancements that are sure to come. A diagnosis of PF will change your life, but life is for the ...

Pulmonary fibrosis (PF) is a disease of the respiratory system caused by scarring (fibrosis) in the lungs, which makes it harder for patients to breathe. Based on the underlying cause of the scarring, ...

Pulmonary fibrosis (PF), as its name suggests, is a disease marked by scarring — or fibrosis — of the lungs, leading to shortness of breath. PF is part of a larger group of more than 200 lung ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs, leading to breathing difficulties, dry cough, muscle aches, and unintended weight loss. Because these symptoms also are ...

PF patients often notice breathlessness when exercising or exerting themselves physically, but as the disease progresses, dyspnea begins to occur even when engaging in simple tasks such as walking, ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs. Scar tissue development can interfere with the lungs’ ability to deliver oxygen to the bloodstream, as well as with ...

Columnist Samuel Kirton attended the Pulmonary Fibrosis Foundation's Summit 2025, where the group's five-year strategic plan was unveiled.

Esbriet (pirfenidone) is an oral treatment for idiopathic pulmonary fibrosis (IPF) that was originally developed by Intermune, which later merged with Roche. Esbriet was first approved in the European ...